ReviewCureus2026
Comparison of Diagnostic and Therapeutic Protocols for Chronic Obstructive Pulmonary Disease (COPD): Global Initiative for Chronic Obstructive Lung Disease (GOLD) vs. American Thoracic Society/European Respiratory Society (ATS/ERS) Guidelines.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity and mortality. International clinical practice guidelines, specifically the 2025 Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the joint American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines, provide standardized frameworks for its diagnosis and management. This narrative review compares these two frameworks, highlighting the trade-off between GOLD's clinical simplicity and the ATS/ERS emphasis on physiological precision. Key areas of divergence include diagnostic thresholds (fixed ratio vs. lower limit of normal), treatment classification systems (GOLD's ABE tool vs. ATS/ERS phenotype-driven care), and the use of biomarkers like blood eosinophils. Understanding these nuances is critical for clinicians to optimize diagnostic labeling and long-term therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.